Erythropoietic agents, iron and hemoglobin - What happens beyond the trial setting: Observational data from the ANZDATA Registry

Hemodialysis International

Volumn 8, Issue 3, 2004, Pages 257-264

  McDonald, Stephen P ^a   Marshall, Mark R ^a,b   Kerr, Peter G ^a,c   Russ, Graeme R ^a,d  

^a ANZDATA Registry   (Australia)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c MONASH MEDICAL CENTRE   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Ferritin; Registry; Transferrin

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; TRANSFERRIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NEW ZEALAND; PERITONEAL DIALYSIS; PREVALENCE; RACE DIFFERENCE; REGISTER; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TRANSFERRIN BLOOD LEVEL;

EID: 22644446697     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1492-7535.2004.01103.x     Document Type: Article

References (31)

1. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339(9):584-590.
2. urea in a simple and accurate way. Am J Kidney Dis. 1990; 15(1): 40-45.
3. Stata Corporation. Intercooled Stata, Version 70. College Station, TX: Stata Corporation, 1999.
4. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measure. 1960; 20:37-46.
5. Russ GR. ANZDATA Registry Report. Adelaide, Australia and New Zealand Dialysis and Transplant Registry, 2001.
6. Pharmaceutical Benefits Advisory Committee. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners, 1 February 2002. Canberra: Commonwealth of Australia, 2002.
7. PHARMAC: Pharmaceutical Management Agency. New Zealand Pharmaceutical Schedule. Wellington, Pharmaceutical Management Agency, 2001.
8. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant. 1991; 6(1):31-37.
9. Singh NP, Chandrashekhar, Nair M, Anuradha S, Kohli R, Agarwal SK. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure. J Assoc Physicians India. 2000; 48(3):301-306.
10. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant. 1999; 14(Suppl 2):29-36.
11. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol. 1991; 35(6):280-287.
12. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000; 58(3): 1325-1335.
13. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant. 1999; 14(5):1182-1187.
14. Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol. 1993; 39(2):97-102.
15. Ansell D, Feest T, UK. UK Renal Registry Report. Bristol: UK Renal Registry, 2002.
16. US Renal Data System, USRDS Annual Data Report (ADR) Atlas [Internet]. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003. Available from: http://www.usrds.org/atlas.htm
17. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33(1):63-72.
18. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001; 37(3): 564-572.
19. Fishbane S, Lynn RI. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis. 1995; 25(3): 426-432.
20. Bovy C, Tsobo C, Crapanzano L, Rorive G, Beguin Y, Albert A, Paulus JM. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int. 1999; 56(3):1113-1119.
21. Cullen P, Soffker J, Hopfl M, Bremer C, Schlaghecken R, Mehrens T, Assmann G, Schaefer RM. Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant. 1999; 14(3):659-665.
22. Jones CH, Richardson D, Ayers S, Newstead CG, Will EJ, Davison AM. Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Nephrol Dial Transplant. 1998; 13(11):2873-2876.
23. Schaefer RM, Schaefer L. The hypochromic red cell: A new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med. 1995; 23(1-2): 83-88.
24. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997; 52(1):217-222.
25. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram MM. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997; 30(6):912-922.
26. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001; 60(6): 2406-2411.
27. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997; 29(3):319-333.
28. Lynn KL, Mitchell TR, Shepperd J. Serum ferritin concentration in patients receiving maintenance hemodialysis. Clin Nephrol. 1980; 14(3):124-127.
29. Bell JD, Kincaid WR, Morgan RG, Bunce H 3rd, Alperin JB, Sarles HE, Remmers AR Jr. Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis. Kidney Int. 1980; 17(2):237-241.
30. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron. 1991; 57(2):175-182.
31. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA; Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int. 2001; 60(1):300-308.